SI0652005T1 - Methods for inhibiting endometriosis - Google Patents

Methods for inhibiting endometriosis

Info

Publication number: SI0652005T1
Authority: SI; Slovenia
Prior art keywords: chem; methods; inhibiting endometriosis; endometriosis; inhibiting
Prior art date: 1993-10-15

Application number

SI9430388T

Other languages

English (en)

Inventor

Larry John Black

George Joseph Cullinan

Michael William Draper

Charles David Jones

David Edward Seyler

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-15

Filing date

1994-10-13

Publication date

2001-12-31

1994-10-13 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2001-12-31 Publication of SI0652005T1 publication Critical patent/SI0652005T1/xx

Links

201000009273 Endometriosis Diseases 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title abstract 2
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Cable Transmission Systems, Equalization Of Radio And Reduction Of Echo (AREA)

SI9430388T 1993-10-15 1994-10-13 Methods for inhibiting endometriosis SI0652005T1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/138,643 US5461065A (en)	1993-10-15	1993-10-15	Methods for inhibiting endometriosis
EP94307528A EP0652005B1 (en)	1993-10-15	1994-10-13	Methods for inhibiting endometriosis

Publications (1)

Publication Number	Publication Date
SI0652005T1 true SI0652005T1 (en)	2001-12-31

Family

ID=22482966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9430388T SI0652005T1 (en)	1993-10-15	1994-10-13	Methods for inhibiting endometriosis

Country Status (25)

Country	Link
US (2)	US5461065A (cs)
EP (1)	EP0652005B1 (cs)
JP (1)	JPH07188014A (cs)
KR (1)	KR950010893A (cs)
CN (1)	CN1049335C (cs)
AT (1)	ATE203404T1 (cs)
AU (1)	AU677700B2 (cs)
CA (1)	CA2118092A1 (cs)
CZ (1)	CZ287246B6 (cs)
DE (1)	DE69427800T2 (cs)
DK (1)	DK0652005T3 (cs)
ES (1)	ES2157957T3 (cs)
GR (1)	GR3036971T3 (cs)
HU (1)	HUT71235A (cs)
IL (1)	IL111284A (cs)
NO (1)	NO311242B1 (cs)
NZ (1)	NZ264677A (cs)
PH (1)	PH31261A (cs)
PT (1)	PT652005E (cs)
RU (1)	RU2157203C2 (cs)
SG (1)	SG43319A1 (cs)
SI (1)	SI0652005T1 (cs)
TW (1)	TW296382B (cs)
UA (1)	UA26930C2 (cs)
ZA (1)	ZA948029B (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
USRE38968E1 (en)	1992-07-28	2006-02-07	Eli Lilly And Company	Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en)	1992-07-28	2006-03-28	Eli Lilly And Company	Methods for inhibiting bone loss
TW366342B (en) *	1992-07-28	1999-08-11	Lilly Co Eli	The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en)	1993-01-28	1997-01-21	Neorx Corporation	Method for identifying an agent which increases TGF-beta levels
WO1994026303A1 (en)	1993-05-13	1994-11-24	Neorx Corporation	Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5457116A (en) *	1993-10-15	1995-10-10	Eli Lilly And Company	Methods of inhibiting uterine fibrosis
US5478847A (en)	1994-03-02	1995-12-26	Eli Lilly And Company	Methods of use for inhibiting bone loss and lowering serum cholesterol
ZA956988B (en) *	1994-08-22	1997-02-21	Lilly Co Eli	Methods of inhibiting primary endometrial hyperplasia.
US5843964A (en) *	1994-09-22	1998-12-01	Eli Lilly And Company	Methods of inhibiting endometrial mitoses
US5554600A (en) *	1995-01-20	1996-09-10	Eli Lilly And Company	Methods for inhibiting endometriosis
DE69600709T2 (de) *	1995-06-07	1999-03-18	Eli Lilly And Co., Indianapolis, Ind.	Verbindungen mit N-Acyliertem Piperidin in der Seitenkette und Zusammensetzungen
KR970002795A (ko)	1995-10-30	1997-01-28	모리 하루오	네비게이션(navigation)장치
IL120266A (en) *	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) *	1996-02-28	2001-06-23	Pfizer	New therapeutic uses of estrogen agonists
CA2214072C (en) *	1996-08-29	2006-11-14	Eli Lilly And Company	Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
WO1998046588A2 (en) *	1997-04-11	1998-10-22	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
US5942539A (en) *	1997-10-03	1999-08-24	Wake Forest University	Methods of treating or preventing endometriosis with phytoestrogens
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
KR20010080254A (ko) *	1998-11-26	2001-08-22	야마구찌 다까시	주기 투여용 의약조성물
CZ20013912A3 (cs)	1999-05-04	2002-05-15	Strakan Limited	Androgen glykosid, sloučenina, testosteron-ß-D-glukosid, 5 alfa-Dihydrotestosteron- 17ß-D-glukosid, farmaceutický prostředek a pouľití sloučeniny
AU2002235348A1 (en) *	2001-01-17	2002-07-30	Praecis Pharmaceuticals Inc.	Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
WO2002094788A1 (en) *	2001-05-22	2002-11-28	Eli Lilly And Company	2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
EP1401446B1 (en) *	2001-05-22	2005-02-09	Eli Lilly And Company	Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
TW200407124A (en) *	2002-06-25	2004-05-16	Wyeth Corp	Use of thio-oxindole derivatives in treatment of hormone-related conditions
US20060106010A1 (en) *	2003-05-27	2006-05-18	Black Larry J	Methods for inhibiting bone loss
KR20160088947A (ko)	2010-06-16	2016-07-26	앙도르쉐르슈 인코포레이티드	에스트로겐-관련 질병의 치료 또는 예방 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) *	1981-04-03	1983-04-19	Eli Lilly And Company	Synthesis of acylated benzothiophenes
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) *	1987-03-24	1991-12-24	University Of Pennsylvania	Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) *	1988-10-31	1995-03-07	Endorecherche Inc.	Anti-estrogenic compounds and compositions
SE500453C2 (sv) *	1991-10-07	1994-06-27	Karobio Ab	Ett in vitro förfarande för utvärdering av en substans effekter
JP3157882B2 (ja) *	1991-11-15	2001-04-16	帝国臓器製薬株式会社	新規なベンゾチオフエン誘導体

1993
- 1993-10-15 US US08/138,643 patent/US5461065A/en not_active Expired - Lifetime
1994
- 1994-10-12 UA UA94105917A patent/UA26930C2/uk unknown
- 1994-10-13 ZA ZA948029A patent/ZA948029B/xx unknown
- 1994-10-13 CA CA002118092A patent/CA2118092A1/en not_active Abandoned
- 1994-10-13 RU RU94036772/14A patent/RU2157203C2/ru active
- 1994-10-13 IL IL11128494A patent/IL111284A/xx not_active IP Right Cessation
- 1994-10-13 DE DE69427800T patent/DE69427800T2/de not_active Expired - Fee Related
- 1994-10-13 EP EP94307528A patent/EP0652005B1/en not_active Expired - Lifetime
- 1994-10-13 ES ES94307528T patent/ES2157957T3/es not_active Expired - Lifetime
- 1994-10-13 AU AU75787/94A patent/AU677700B2/en not_active Ceased
- 1994-10-13 PH PH49186A patent/PH31261A/en unknown
- 1994-10-13 DK DK94307528T patent/DK0652005T3/da active
- 1994-10-13 CN CN94117125A patent/CN1049335C/zh not_active Expired - Fee Related
- 1994-10-13 KR KR1019940026164A patent/KR950010893A/ko not_active Ceased
- 1994-10-13 SI SI9430388T patent/SI0652005T1/xx unknown
- 1994-10-13 CZ CZ19942537A patent/CZ287246B6/cs not_active IP Right Cessation
- 1994-10-13 SG SG1996008246A patent/SG43319A1/en unknown
- 1994-10-13 NZ NZ264677A patent/NZ264677A/en unknown
- 1994-10-13 HU HU9402959A patent/HUT71235A/hu unknown
- 1994-10-13 NO NO19943879A patent/NO311242B1/no not_active IP Right Cessation
- 1994-10-13 TW TW083109467A patent/TW296382B/zh active
- 1994-10-13 PT PT94307528T patent/PT652005E/pt unknown
- 1994-10-13 JP JP6247764A patent/JPH07188014A/ja active Pending
- 1994-10-13 AT AT94307528T patent/ATE203404T1/de not_active IP Right Cessation
1995
- 1995-04-14 US US08/422,387 patent/US5693656A/en not_active Expired - Fee Related
2001
- 2001-10-22 GR GR20010401841T patent/GR3036971T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69427800T2 (de)	2001-12-06
RU94036772A (ru)	1996-08-27
HUT71235A (en)	1995-11-28
UA26930C2 (uk)	1999-12-29
IL111284A0 (en)	1994-12-29
KR950010893A (ko)	1995-05-15
JPH07188014A (ja)	1995-07-25
HU9402959D0 (en)	1995-02-28
US5461065A (en)	1995-10-24
CZ253794A3 (en)	1995-05-17
DK0652005T3 (da)	2001-09-24
CN1107043A (zh)	1995-08-23
RU2157203C2 (ru)	2000-10-10
US5693656A (en)	1997-12-02
NZ264677A (en)	1997-07-27
AU7578794A (en)	1995-05-04
NO311242B1 (no)	2001-11-05
SG43319A1 (en)	1997-10-17
PT652005E (pt)	2001-11-30
DE69427800D1 (de)	2001-08-30
AU677700B2 (en)	1997-05-01
CZ287246B6 (en)	2000-10-11
CN1049335C (zh)	2000-02-16
NO943879D0 (no)	1994-10-13
PH31261A (en)	1998-06-18
EP0652005A1 (en)	1995-05-10
ES2157957T3 (es)	2001-09-01
GR3036971T3 (en)	2002-01-31
NO943879L (no)	1995-04-18
TW296382B (cs)	1997-01-21
ZA948029B (en)	1996-04-15
ATE203404T1 (de)	2001-08-15
CA2118092A1 (en)	1995-04-16
EP0652005B1 (en)	2001-07-25
IL111284A (en)	2000-02-29

Publication	Publication Date	Title
PH31261A (en)	1998-06-18	Methods for inhibiting endometriosis.
ZA9410084B (en)	1996-06-19	Methods of inhibiting thrombin
HU9403667D0 (en)	1995-02-28	Methods of inhibiting seborrhea and acne
PH31596A (en)	1998-11-03	Methods of inhibiting uteine fibrosis.
IL111289A0 (en)	1994-12-29	Methods for inhibiting angiogenesis and angiogenic diseases
HU9403663D0 (en)	1995-02-28	Methods of inhibiting dysfunctional uterine bleeding
ZA948028B (en)	1996-04-15	Methods for inhibiting cartilage degradation
PH31325A (en)	1998-07-06	Methods of increasing thrombomodulin expression.
HU9403654D0 (en)	1995-02-28	Methods of inhibiting ovarian dysgenesis, delayed puberty or sexual infantilism
PH31440A (en)	1998-11-03	Method of inhibiting hirsutism and alopecia in women.